The Petri Dish: Morphic, J&J part ways; FDA committee to review another Biogen drug

Waltham biotech Morphic Holding Inc. is no longer working with Johnson & Johnson Inc. after the pharma giant elected to terminate a nearly four-year-old collaboration agreement.